Zafgen, Inc. (NASDAQ: ZFGN) Starts Presentation at 29th Annual Roth Conference
Zafgen (NASDAQ: ZFGN) is a biopharmaceutical company focused on developing therapeutics for patients suffering from obesity and obesity-related disorders. Its lead product candidate is the Beloranib, an injection, which is in phase III clinical trials for the treatment of obesity and hyperphagia in patients with Prader-Willi syndrome; that has completed phase II clinical trials to treat hypothalamic injury-associated obesity, including craniopharyngioma-associated obesity; and which has completed phase IIb clinical trials for the treatment of severe obesity in the general population. The company is also developing ZGN-839, a liver-targeted methionine aminopeptidase 2 (MetAP2) inhibitor that is in pre-clinical studies for the…







